Friday, April 11, 2025, Denver, Colorado, 12:15 PM – 1:45 PM Mountain Time (2:15 PM – 3:45 PM Eastern Time)

Understanding the Current Paradigm and New Approaches in the Care of Patients with Ovarian Cancer

A Complimentary NCPD Symposium Held During the 50th Annual ONS Congress

 

 

 

Register for in-person Register for webcast

Location
Hyatt Regency Denver
at Colorado Convention Center
650 15th Street
Denver, Colorado
Hotel Phone: (303) 436-1234

Program Schedule — Mountain Time
11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

Meeting Room
Capitol Ballroom (Fourth Floor)
 
 
Faculty
Courtney Arn, CNP
The James Cancer Hospital
and Solove Research Institute
The Ohio State University
Columbus, Ohio

Jennifer Filipi, MSN, NP
Department of Gynecologic Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

David M O'Malley, MD
Director and Professor
Division of Gynecologic Oncology in Obstetrics
and Gynecology
John G Boutselis Chair in Gynecologic Oncology
The Ohio State University and
The James Comprehensive Cancer Center
Columbus, Ohio


Shannon N Westin, MD, MPH, FASCO, FACOG
Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas



Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, GSK, and Merck during the Oncology Nursing Society’s (ONS) 50th Annual Congress, April 9-13, 2025 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Mountain Time
11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

Importance of Genetic Testing in the Care of Patients with Newly Diagnosed Advanced Ovarian Cancer (OC)

  • Similarities and differences between germline and somatic genetic mutations
  • Incidence and clinical significance of BRCA mutations and other germline or somatic alterations in OC, such as PALB2, ATM and RAD51C/D
  • Definition and frequency of homologous recombination deficiency (HRD) in OC; rationale for determining HRD status and available testing methods
  • Current roles of next-generation sequencing and germline sequencing in the management of advanced OC; similarities and differences among available genetic testing platforms
  • Purpose and potential benefits of genetic counseling after a diagnosis of OC

Role of PARP Inhibitor Maintenance in Therapy for Newly Diagnosed Advanced OC

  • Mechanism of antitumor activity of PARP inhibitors and rationale for their use as maintenance therapy for patients with OC
  • Similarities and differences among various PARP inhibitors approved for OC
  • Long-term findings from Phase III studies supporting the use of olaparib, niraparib and olaparib/bevacizumab as maintenance therapy for patients with newly diagnosed OC
  • Clinical, biological and practical factors in the selection of olaparib, niraparib or olaparib/bevacizumab as up-front maintenance therapy
  • Published and emerging data with and potential role of PARP inhibitors in combination with anti-PD-1/PD-L1 antibodies in the treatment of advanced OC

PARP Inhibitors for Relapsed/Refractory OC

  • Defining “platinum-sensitive” and “platinum-resistant” in relapsed OC
  • Long-term follow-up from pivotal trials evaluating niraparib, olaparib and rucaparib for patients with platinum-sensitive and platinum-resistant recurrent OC
  • Rationale for the withdrawal of various indications for olaparib, niraparib and rucaparib and implications for the management of relapsed/refractory disease
  • Current clinical utility, if any, of rechallenge with a PARP inhibitor in patients who have experienced disease progression on or after prior PARP inhibitor therapy

Side Effects and Other Practical Considerations with PARP Inhibitors

  • Initial dosing and appropriate dose-modification strategies for approved PARP inhibitors
  • Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors in patients with OC
  • Optimal monitoring for and management of common PARP inhibitor-related toxicities
  • Long-term risk of acute myeloid leukemia or myelodysplastic syndromes with PARP inhibitor therapy
  • Importance of adherence for patients receiving long-term oral medications, including PARP inhibitors; strategies to encourage and assess adherence

Current and Potential Role of Mirvetuximab Soravtansine in OC Treatment

  • Frequency of folate receptor alpha (FRα) expression in OC and scientific rationale for targeting this cell-surface receptor protein
  • Mechanism of action and structural components of mirvetuximab soravtansine
  • Available research findings with mirvetuximab soravtansine for FRα-high platinum-resistant OC
  • FDA approval of mirvetuximab soravtansine; implications for biomarker assessment and current OC management
  • Published positive findings with mirvetuximab soravtansine for platinum-sensitive advanced OC; ongoing evaluation and potential utility in this setting

Toxicities Associated with Mirvetuximab Soravtansine

  • Pathophysiology and incidence of ocular toxicities observed with mirvetuximab soravtansine
  • Monitoring and management techniques for mirvetuximab soravtansine-related ocular events
  • Importance of collaboration with eye care specialists in the care of patients receiving mirvetuximab soravtansine
  • Spectrum, frequency, severity and timing of other common toxicities reported with mirvetuximab soravtansine; optimal management approaches

Other Available and Investigational Novel Strategies for OC

  • Frequency of HER2 expression in advanced OC; optimal timing of and approach to testing
  • FDA approval of trastuzumab deruxtecan for pretreated HER2-positive solid tumors; implications for OC management
  • Biological rationale for targeting CDH6 in OC; mechanism of antitumor activity of the novel CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd)
  • Early research findings with and ongoing evaluation of R-DXd for heavily pretreated platinum-resistant advanced OC
  • Other promising agents and strategies under investigation for advanced OC

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer (OC).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC, and counsel appropriate individuals regarding personalized treatment recommendations.
  • Assess available clinical trial data with and newly adapted indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC in order to optimally and appropriately incorporate these agents into current management algorithms.
  • Evaluate the biological rationale for and published clinical research data with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings.
  • Appraise relevant biological, patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
  • Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods to test for this newly relevant biomarker.
  • Understand the structural components and mechanism of action of antibody-drug conjugates directed at folate receptor alpha, and discuss current research findings with these agents.
  • Appreciate the side effects associated with various systemic therapies commonly employed for OC, and use this information to develop supportive management plans for patients.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2025/OvarianCancer/ILNA

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Filipi has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Arn — Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genmab US Inc, ImmunoGen Inc, Merck, Pfizer Inc. Dr O'Malley — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics, Duality Biologics, Genmab US Inc, GSK, Merck, MSD, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Verastem Inc; Contracted Research: AbbVie Inc, Adaptimmune, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, BeiGene Ltd, Bristol Myers Squibb, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals Inc, Duality Biologics, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Exelixis Inc, Genelux Corporation, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Imvax Inc, Incyte Corporation, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, Onconova Therapeutics Inc, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, R-Pharm US, Rubius Therapeutics, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Tesaro, A GSK Company, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Nonrelevant Financial Relationships: Amarex Clinical Research, GOG Foundation, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG Foundation, SWOG.

MODERATOR — Dr Westin — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Clovis Oncology, Corcept Therapeutics, Daiichi Sankyo Inc, Eisai Inc, EQRx, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Seagen Inc, Verastem Inc, Vincerx Pharma, Zentalis Pharmaceuticals, ZielBio; Contracted Research (to Institution): AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings, Clovis Oncology, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Zentalis Pharmaceuticals.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Merck.

Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234

Meeting Room
Capitol Ballroom (Fourth Floor)

The Hyatt Regency Denver at Colorado Convention Center is the headquarters hotel for the 2025 ONS Congress and is adjacent to the Colorado Convention Center.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer.

There is no registration fee for this event. For the in-person symposium in Denver, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2025 ONS Congress.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.